Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genentech/Novartis Xolair goes before advisory committee

Executive Summary

Asthma treatment Xolair (omalizumab) will go before FDA's Pulmonary-Allergy Drugs Advisory Committee on May 15. Genentech and Novartis are seeking an indication for treatment of moderate-to-severe allergic asthma in adolescents and adults. The firms narrowed the requested indication after FDA deemed the number of patients studied for a younger age group and an allergic rhinitis indication to be insufficient in a July 5, 2001 "complete response" letter. The meeting will be held at the Holiday Inn in Gaithersburg, Md. beginning at 8 a.m. [To watch a 1webcast of this meeting and other meetings, go to FDAAdvisoryCommittee.com]...
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS041528

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel